TickerFacts.

Pelthos Therapeutics Inc. (PTHS): Cash & Equivalents

Annual figures by period end, from SEC filings.

$17.97M
As of 2025-12-31
$24.19M
As of 2026-06-30
n/m
3-year compound annual growth
2022-12-31: $100.0K2023-12-31: $100.0K2024-12-31: $513.0K2025-12-31: $17.97M$17.97M
2022-12-31 Cash & Equivalents (USD) 2025-12-31
Period endedCash & EquivalentsChange YoYSource filing
2025-12-31$17.97Mn/m2026-03-19, Balance as of period end
2024-12-31$513.0K+413.0%2026-03-19, Balance as of period end
2023-12-31$100.0K0.0%2024-04-16, Balance as of period end
2022-12-31$100.0Kn/a2024-04-16, Balance as of period end

Cash & Equivalents at similar companies

Companies with the same SEC industry code (Biological Products, (No Diagnostic Substances)), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedCash & EquivalentsChange YoY
Pelthos Therapeutics Inc. (PTHS)2025-12-31$17.97Mn/m
Relay Therapeutics, Inc. (RLAY)2025-12-31$84.02M-32.4%
LENZ Therapeutics, Inc. (LENZ)2025-12-31$25.18M+24.9%
Lineage Cell Therapeutics, Inc. (LCTX)2025-12-31$40.79M-10.9%
Alector, Inc. (ALEC)2025-12-31$65.80M+99.3%
Metagenomi Therapeutics, Inc. (MGX)2025-12-31$41.72M+52.3%
Caribou Biosciences, Inc. (CRBU)2025-12-31$12.36M-24.1%
TScan Therapeutics, Inc. (TCRX)2025-12-31$152.41M-14.7%
Alpha Cognition Inc. (ACOG)2025-12-31$66.05M+36.0%

Compare PTHS, RLAY, LENZ, LCTX side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗